NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer

doi:10.3748/wjg.v31.i11.100785

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1235)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series.

Item

Count

PDF

HTML

716

Figures (1-8)

Sum=836

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

183

Sum=269

Publishing Process of This Article

Item

Count

Browse

Download

Sum=97

Mar 21, 2025 (publication date) through Apr 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Mar 21, 2025; 31(11): 100785
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.100785

Full Size Figure Download Figure

Figure 8 Schematic diagram of SIRT1 inhibition-driven glycolysis and oxaliplatin resistance in colorectal cancer cells. DNA damage, a crucial driver of increased glycolysis in colorectal cancer (CRC) cells, exerts its effect primarily through PARP activation, which depletes intracellular NAD+, thereby inhibiting SIRT1 expression. Enhanced glycolysis in CRC cells via SIRT1 inhibition, which contributes to oxaliplatin resistance. CRC: Colorectal cancer.

Citation: Niu YR, Xiang MD, Yang WW, Fang YT, Qian HL, Sun YK. NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. World J Gastroenterol 2025; 31(11): 100785
URL: https://www.wjgnet.com/1007-9327/full/v31/i11/100785.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i11.100785